Tocilizumab biosimilar - Mycenax Biotech

Drug Profile

Tocilizumab biosimilar - Mycenax Biotech

Alternative Names: LusiNEX

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mycenax Biotech
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Juvenile rheumatoid arthritis; Rheumatoid arthritis

Most Recent Events

  • 09 Oct 2017 Tocilizumab biosimilar - Mycenax Biotech is available for licensing as of 09 Oct 2017.
  • 09 Oct 2017 Therapeutic Goods Administration approves an application for initiation of a phase I trial (In volunteers) of tocilizumab biosimilar in Australia
  • 06 Oct 2017 Mycenax Biotech announces intention to submit a Clinical Trial Application for Rheumatoid arthritis and Juvenile rheumatoid arthritis in Europe in October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top